Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 1.00 |
| ▸ | F2 | P00734 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.82 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.59 |
| ▸ | PLG | P00747 | 2/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.58 |
| ▸ | PLAT | P00750 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ym-60828 SCHEMBL29374349 | 1.00 | F10 (1.00) | F10F2KCNH2PRSS1PLG | |
| Ym-60828 SCHEMBL29374786 | 1.00 | F10 (1.00) | F10F2KCNH2PRSS1PLG | |
| Ym-60828 SCHEMBL6158242 | 0.99 | F10 (0.98) | F10F2KCNH2PRSS1PLG | |
| Ym-60828 SCHEMBL30693688 | 0.98 | F10 (0.95) | F10F2KCNH2PRSS1PLG | |
| SCHEMBL20248862 | 0.95 | F10 (0.90) | F10F2KCNH2PRSS1PLG | |
| Hydrochloric Acid SCHEMBL6954901 | 0.94 | F10 (0.90) | F10F2KCNH2PRSS1PLG | |
| SCHEMBL19699428 | 0.92 | F10 (0.85) | F10F2KCNH2PRSS1PLG | |
| Hydrochloric Acid SCHEMBL6959811 | 0.92 | F10 (0.85) | F10F2KCNH2PRSS1PLG | |
| Hydrochloric Acid SCHEMBL8801687 | 0.92 | F10 (0.84) | F10F2KCNH2PRSS1PLG | |
| SCHEMBL19691082 | 0.92 | F10 (0.84) | F10F2KCNH2PRSS1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240424175-A1 | ANTICOAGULANT COMPOUNDS COMPRISING CHELATING AGENTS AND CATIONIC ANTI-COAGULATION ENHANCERS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2024-12-26 | — | — | US | claimed |
| US-11654036-B2 | Anticoagulant compounds and methods and devices for their use | ELIXIR MEDICAL CORPORATION (US) | 2023-05-23 | — | — | US | claimed |
| US-20220039976-A1 | ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2022-02-10 | — | — | US | claimed |
| WO-2006110726-A2 | DOSAGE FORMULATIONS AND METHODS OF TREATMENT AND PREVENTION | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | claimed |
| US-20050187249-A1 | An aqueous solution of a physiologically active substance which may have a substituent and which has an amidino group, the solution having a pH > 2 and -/< than 4; storage stability; parental injections; 2-[4-[((3S)-1-acetoimidoyl-3-pyrrolidinyl)oxy]phenyl] -3-(7-amidino-2-naphthyl)propionic acid; kits | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-08-25 | — | — | US | claimed |
| EP-1504755-A1 | LYOPHILIZATION PRODUCT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-02-09 | — | — | EP | claimed |
| EP-0798295-B1 | NOVEL AMIDINONAPHTHYL DERIVATIVE OR SALT THEREOF | YAMANOUCHI PHARMA CO LTD (JP) | 2003-02-26 | — | — | EP | claimed |
| EP-1043020-A1 | MEDICINAL COMPOSITION FOR PERCUTANEOUS ADMINISTRATION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-10-11 | — | — | EP | claimed |
| EP-0966973-A1 | SORBEFACIENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-12-29 | — | — | EP | claimed |
| EP-0953359-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-11-03 | — | — | EP | claimed |
| EP-0798295-A1 | NOVEL AMIDINONAPHTHYL DERIVATIVE OR SALT THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-10-01 | — | — | EP | claimed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | disclosed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | disclosed |
| US-20230165874-A1 | ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR PULMONARY USE | ELIXIR MEDICAL CORPORATION (US) | 2023-06-01 | — | — | US | disclosed |
| WO-2023096800-A1 | ANTICOAGULANT COMPOUNDS COMPRISING CHELATING AGENTS AND CATIONIC ANTI-COAGULATION ENHANCERS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2023-06-01 | — | — | WO | disclosed |
| EP-1110556-A1 | PREVENTIVES/REMEDIES FOR MULTIPLE ORGAN FAILURE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-27 | — | — | EP | disclosed |
| EP-1043020-A1 | MEDICINAL COMPOSITION FOR PERCUTANEOUS ADMINISTRATION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-10-11 | — | — | EP | disclosed |
| EP-0966973-A1 | SORBEFACIENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-12-29 | — | — | EP | disclosed |
| EP-0953359-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-11-03 | — | — | EP | disclosed |
| EP-0798295-A1 | NOVEL AMIDINONAPHTHYL DERIVATIVE OR SALT THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | ACE2, SARS1, ACE | F10 4535/4885F2 660/4885KCNH2 3957/4885 |
| US-20050187249-A1 | An aqueous solution of a physiologically active substance which may have a substituent and which has an amidino group, the solution having a pH > 2 and -/< than 4; storage stability; parental injections; 2-[4-[((3S)-1-acetoimidoyl-3-pyrrolidinyl)oxy]phenyl] -3-(7-amidino-2-naphthyl)propionic acid; kits | NGLY1, IDE, NPPA | F10 98/4885F2 457/4885KCNH2 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.